NCT00336583View on ClinicalTrials.gov

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

January 31, 2008

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Oxaliplatin

Oxaliplatin, 130 mg per square meter, on day 1

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Boryung Pharmaceutical Co., Ltd

INDUSTRY

lead

Asan Medical Center

OTHER